{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:30:46Z","timestamp":1786347046707,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":221,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Infectious Diseases"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>People living with HIV (PLWH) remain at increased risk of diffuse large B\u2010cell lymphoma (DLBCL). Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola\u2010R\u2010CHP) has emerged as a standard first\u2010line option for DLBCL in the general population, but the pivotal POLARIX trial excluded PLWH, leaving limited evidence on feasibility with contemporary antiretroviral therapy (ART).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 61\u2010year\u2010old man presented with progressive anorexia and weight loss. With durable virologic suppression (plasma HIV\u20101 RNA below 20 copies\/mL) and immune reconstitution (CD4+ T\u2010cell count approximately 300\u2009cells\/\u00b5L) on bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF), he was diagnosed with nongerminal center B\u2010cell DLBCL (Lugano stage II; International Prognostic Index score 2). Pola\u2010R\u2010CHP was administered every 21\u2009days for six cycles (Cycle 1: inpatient and Cycles 2\u20136: outpatient), followed by two additional rituximab cycles, without ART modification. No grade 3\u20134 nonhematologic toxicity, febrile neutropenia, or serious infections occurred. HIV\u20101 RNA remained below 20\u2009copies\/mL throughout treatment, and CD4+ T\u2010cell counts showed no clinically meaningful decline. End\u2010of\u2010treatment fluorodeoxyglucose positron emission tomography\/computed tomography (FDG\u2010PET\u2013CT) demonstrated a partial metabolic response with two small residual FDG\u2010avid foci (\u223c1\u2009cm; SUVmax \u223c4\u20105). At the last follow\u2010up, the patient had no clinical or radiologic evidence of progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Outpatient\u2010delivered Pola\u2010R\u2010CHP appeared feasible in PLWH with virologic suppression and immune reconstitution receiving BIC\/FTC\/TAF, without virologic breakthrough or unexpected toxicity. Prospective inclusion of PLWH in polatuzumab\u2010containing frontline studies is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/crdi\/7583461","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:13:02Z","timestamp":1786345982000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIV\u2010Associated Diffuse Large B\u2010Cell Lymphoma Treated With Outpatient Pola\u2010R\u2010CHP Without Antiretroviral Therapy Modification: A Case Report"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4780-9137","authenticated-orcid":false,"given":"Yoshikazu","family":"Ikoma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0463-2326","authenticated-orcid":false,"given":"Nobuyuki","family":"Tetsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-7777","authenticated-orcid":false,"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-2058","authenticated-orcid":false,"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_2_13_1_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051447"},{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123191"},{"key":"e_1_2_13_3_2","article-title":"NCCN Clinical Practice Guidelines in Oncology: HIV-Related B-Cell Lymphomas [Internet]","author":"National Comprehensive Cancer Network","year":"2025","journal-title":"National Comprehensive Cancer Network (NCCN)"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2115304"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7338"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"e_1_2_13_9_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A Predictive Model for Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_13_11_2","volume-title":"Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide) Tablets, for Oral Use: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"e_1_2_13_12_2","volume-title":"Polivy (Polatuzumab Vedotin-Piiq) for Injection, for Intravenous Use: Prescribing Information [Internet]","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"e_1_2_13_13_2","volume-title":"Liverpool HIV Drug Interactions","author":"University of Liverpool","year":"2025"},{"key":"e_1_2_13_14_2","volume-title":"Rituxan (Rituximab) Injection, for Intravenous Use: Prescribing Information [Internet]","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"e_1_2_13_15_2","volume-title":"Cyclophosphamide Injection, for Intravenous Use: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"e_1_2_13_16_2","volume-title":"Doxorubicin Hydrochloride Injection, for Intravenous Use: Prescribing Information [Internet]","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"e_1_2_13_17_2","volume-title":"Rayos (Prednisone) Delayed-Release Tablets, for Oral Use: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"e_1_2_13_18_2","volume-title":"Sitavig (Acyclovir) Buccal Tablets: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2013"},{"key":"e_1_2_13_19_2","volume-title":"Bactrim (Sulfamethoxazole and Trimethoprim) Tablets: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"e_1_2_13_20_2","volume-title":"Neulasta (Pegfilgrastim) Injection, for Subcutaneous Use: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"e_1_2_13_21_2","volume-title":"Otezla (Apremilast) Tablets: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"e_1_2_13_22_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","author":"National Cancer Institute","year":"2017"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.05.4684"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231613"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253039"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220967080"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-10048-0"}],"container-title":["Case Reports in Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdi\/7583461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crdi\/7583461","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdi\/7583461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:13:06Z","timestamp":1786345986000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crdi\/7583461"}},"subtitle":[],"editor":[{"given":"Priya","family":"Gusain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crdi\/7583461"],"URL":"https:\/\/doi.org\/10.1155\/crdi\/7583461","archive":["Portico"],"relation":{},"ISSN":["2090-6625","2090-6633"],"issn-type":[{"value":"2090-6625","type":"print"},{"value":"2090-6633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"7583461"}}